Biliary Atresia

1. Clinical Overview

Summary

Biliary atresia (BA) is a progressive, fibro-obliterative cholangiopathy of the extrahepatic bile ducts that presents in early infancy, representing the most common indication for paediatric liver transplantation worldwide. [1] The condition is characterized by inflammatory destruction and fibrosis of the extrahepatic biliary tree, resulting in complete obstruction of bile flow. Without intervention, BA leads to progressive intrahepatic cholestasis, cirrhosis, and liver failure within the first year of life.

The hallmark presentation is conjugated hyperbilirubinaemia with persistent jaundice beyond the physiological neonatal period, accompanied by acholic (pale) stools and dark urine. Early diagnosis is critical because the primary surgical intervention—the Kasai portoenterostomy (hepatoportoenterostomy)—has a dramatically better prognosis when performed before 60 days of age, with optimal outcomes achieved before 30 days. [2,3] Every day of delay increases the risk of irreversible hepatic fibrosis.

Despite successful Kasai procedures, most patients eventually develop progressive liver disease, with approximately 50-60% requiring liver transplantation by age 2 years and 80% by adulthood. [4] However, with modern surgical techniques and improved transplantation outcomes, long-term survival exceeds 90% at 5 years post-transplant. [5]

Key Facts

• Incidence: 1 in 10,000-18,000 live births in Western populations; 1 in 5,000-9,000 in Asian populations [1,6]
• UK incidence: Approximately 50-60 new cases annually
• Peak presentation: First 2-8 weeks of life
• Pathognomonic triad: Conjugated hyperbilirubinaemia + acholic stools + dark urine
• Critical surgical window: Kasai portoenterostomy ideally performed less than 60 days of age
• Age-dependent success: Jaundice clearance in ~80% if Kasai performed less than 30 days, but less than 20% if > 90 days [3]
• Transplantation need: 50-60% by age 2 years; 80% by adulthood [4]
• Leading indication: Accounts for 40-50% of all paediatric liver transplants [1]
• Long-term survival: > 90% at 5 years post-transplant [5]

Clinical Pearls

The 14-Day Rule: Any term infant with jaundice persisting beyond 14 days of age (21 days for preterm infants) requires a split bilirubin test to differentiate conjugated from unconjugated hyperbilirubinaemia. Conjugated jaundice is never physiological and demands immediate investigation.

Stool Colour Is Diagnostic: Acholic (pale, clay, putty, or chalk-coloured) stools indicate biliary obstruction until proven otherwise. Stool colour charts should be routinely provided to parents during neonatal follow-up, as this simple observation can facilitate earlier diagnosis. [7]

Time Is Liver—Every Day Counts: The success rate of Kasai portoenterostomy declines precipitously with advancing age. Success rates fall from 80% when performed less than 30 days to less than 20% after 90 days. [3] Urgent specialist referral is mandatory for any infant with suspected biliary obstruction.

Triangular Cord Sign: The ultrasonographic "triangular cord" sign—representing the fibrous biliary remnant anterior to the portal vein at the porta hepatis—has high specificity (95-100%) for biliary atresia and should prompt immediate specialist referral. [8,9]

Why This Matters Clinically

Biliary atresia represents a time-critical paediatric emergency, yet delayed diagnosis remains common due to the misconception that "neonatal jaundice is normal." The narrow therapeutic window for optimal surgical intervention means that every healthcare professional caring for neonates must maintain high vigilance. Missing the diagnosis by even 2-3 weeks can transform a potentially manageable condition into one requiring early liver transplantation. The condition's rarity (affecting only 1 in 10,000-15,000 births) paradoxically increases the risk of delayed recognition, as many clinicians may never encounter a case during training.

Public health initiatives, including parental education on stool colour recognition and systematic screening for conjugated hyperbilirubinaemia, have demonstrated measurable improvements in age at diagnosis and surgical outcomes. [7]

---

2. Epidemiology

Incidence & Prevalence

Biliary atresia demonstrates significant geographic and ethnic variation in incidence:

The higher incidence in Asian and Pacific Island populations suggests potential genetic or environmental factors, though the precise aetiology remains unknown. [1]

Demographics

Classification

Biliary atresia is classified into two major clinical subtypes with distinct timing and associations:

Clinical Classification

BASM Syndrome (Biliary Atresia Splenic Malformation)

BASM represents the syndromic form of biliary atresia and includes:

• Splenic anomalies: Polysplenia, asplenia, or splenic hypoplasia
• Laterality defects: Situs inversus, situs ambiguus
• Cardiovascular anomalies: Interrupted inferior vena cava with azygos continuation, cardiac septal defects, anomalous pulmonary venous return
• Gastrointestinal malrotation: Pre-duodenal portal vein
• Absent retrohepatic inferior vena cava: Pathognomonic finding

BASM is associated with poorer prognosis post-Kasai and earlier need for transplantation compared to isolated BA. [1]

Anatomical Classification (French Classification)

Based on the level of extrahepatic bile duct obliteration:

Type III (porta hepatis involvement) is by far the most common anatomical variant and presents the greatest surgical challenge, as microscopic bile ducts at the porta hepatis must establish drainage into the jejunal conduit. [12]

---

3. Pathophysiology

Aetiology

The exact aetiology of biliary atresia remains unknown despite decades of research. Current evidence supports a multifactorial pathogenesis involving genetic susceptibility, immune dysregulation, and potential environmental triggers acting during a critical developmental window. [1,13]

Proposed Aetiological Mechanisms

1. Viral Trigger Hypothesis

• Perinatal viral infection may initiate biliary epithelial injury in genetically susceptible infants
• Implicated viruses: Rotavirus, reovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV)
• Rotavirus has been detected in biliary remnants in some studies, but causality unproven [13]
• Seasonality of cases supports infectious trigger in subset of patients [11]

2. Immune-Mediated Injury

• Aberrant immune response to biliary epithelium drives progressive fibrosis
• Elevated levels of inflammatory cytokines (IL-2, IL-8, TNF-α, IFN-γ) in bile duct tissue [13]
• Autoreactive T-cell infiltration and activated macrophages in portal tracts
• Possible molecular mimicry between viral antigens and biliary epithelial proteins

3. Genetic Susceptibility

• Familial cases rare (less than 1%) but documented, suggesting genetic contribution [1]
• Genome-wide association studies (GWAS) identify susceptibility loci including:
  • ADD3 (cytoskeletal protein gene) associated with BA in Asian populations [14]
  • GPC1 (glypican 1) variants linked to BA susceptibility [14]
• Overlapping genetic pathways with other cholangiopathies

4. Developmental Defect (BASM Syndrome)

• Embryonic form associated with laterality defects suggests disruption of developmental programs during early organogenesis
• Defects in ciliary function and planar cell polarity pathways implicated [1]

Pathogenesis—Progressive Biliary Obliteration

The pathological process follows a predictable sequence:

Phase 1: Inflammatory Cholangitis (Perinatal Period)

• Initial injury to biliary epithelium (likely viral or immune-mediated)
• Infiltration of inflammatory cells (T-cells, macrophages, neutrophils) into bile duct walls
• Release of pro-inflammatory cytokines and chemokines
• Epithelial cell apoptosis and necrosis

Phase 2: Fibro-Obliterative Phase (First Weeks of Life)

• Progressive fibrosis of extrahepatic bile ducts
• Luminal obliteration by fibrous tissue—ducts become solid fibrous cords
• Loss of biliary epithelium replaced by collagenous scar tissue
• Complete obstruction of bile flow from liver to duodenum

Phase 3: Intrahepatic Cholestasis and Injury (Ongoing)

• Bile accumulation within hepatocytes and intrahepatic ducts
• Bile acid toxicity causes hepatocellular damage
• Activation of hepatic stellate cells and myofibroblasts
• Portal and periportal fibrosis develops

Phase 4: Cirrhosis and End-Stage Liver Disease (Months to Years)

• Progressive fibrosis leads to bridging fibrosis and cirrhosis
• Portal hypertension develops (splenomegaly, varices, ascites)
• Synthetic liver dysfunction (coagulopathy, hypoalbuminaemia)
• Hepatorenal syndrome and hepatopulmonary syndrome in advanced cases
• Risk of hepatocellular carcinoma (rare but increased in cirrhotic livers)

Molecular Pathophysiology

Recent research has elucidated key molecular pathways driving biliary fibrosis:

Bile Acid Signalling Dysregulation

• Accumulation of toxic hydrophobic bile acids (chenodeoxycholic acid, cholic acid) in hepatocytes
• Impaired farnesoid X receptor (FXR) signalling disrupts bile acid homeostasis
• Fibroblast growth factor 19 (FGF19) downregulation—FGF19 levels correlate with post-Kasai prognosis [15]

Epithelial-Mesenchymal Transition (EMT)

• Biliary epithelial cells undergo EMT in response to injury
• Transformed cells acquire fibroblast-like properties and contribute to periductal fibrosis
• Mediated by TGF-β, Wnt/β-catenin, and Notch signalling pathways [13]

Oxidative Stress and Hepatocyte Injury

• Cholestasis induces oxidative stress via bile acid-mediated reactive oxygen species (ROS) generation
• Mitochondrial dysfunction and hepatocyte apoptosis
• Activation of pro-fibrotic pathways in hepatic stellate cells

Angiogenic Dysregulation

• Aberrant angiogenesis at porta hepatis may contribute to fibrous remnant formation
• Elevated VEGF and angiopoietin levels detected in biliary tissue [13]

Histopathological Features

Liver biopsy in biliary atresia demonstrates characteristic findings:

The combination of bile duct proliferation, portal fibrosis, and bile plugs in a jaundiced neonate is highly suggestive of extrahepatic biliary obstruction. [16]

---

4. Clinical Presentation

Age at Presentation

• Typical presentation: 2-8 weeks of age (most common at 4-6 weeks)
• Jaundice onset: Newborn period (first days to weeks of life)
• Syndromic BA (BASM): May present earlier with associated anomalies detected antenatally or at birth
• Key point: Jaundice persists or worsens beyond the physiological neonatal period (> 14 days in term infants)

Clinical Features

Symptoms

Signs

Stool Colour—The Key Clinical Clue

The appearance of stools is the most important clinical observation for early diagnosis:

Normal Neonatal Stools:

• Colour: Yellow, mustard, brown, or greenish (bile pigment stercobilin)
• Consistency: Soft, seedy (breastfed) or firmer (formula-fed)

Acholic Stools in Biliary Atresia:

• Colour: Pale, clay, putty, chalk, white, or very light yellow
• Appearance: Lack of brown/green pigmentation
• Variability: May be intermittent initially due to partial obstruction
• Critical point: Persistent acholic stools beyond 1-2 weeks of age mandate urgent investigation [7]

Stool colour charts (e.g., "Yellow Alert" charts) improve parental recognition and have been shown to reduce age at diagnosis when implemented in population screening programs. [7]

Red Flags—Urgent Specialist Referral Indicated

[!CAUTION] Immediate Referral to Paediatric Hepatology/Surgery Required If:

• Jaundice persisting beyond 14 days of age in term infants (21 days in preterm)
• Acholic (pale, clay, chalk-coloured) stools at any age
• Dark urine in a jaundiced neonate
• Conjugated bilirubin > 20% of total bilirubin OR conjugated bilirubin > 25 μmol/L (1.5 mg/dL)
• Hepatomegaly with jaundice
• Unexplained coagulopathy (prolonged PT/INR unresponsive to vitamin K)
• Any neonate with cholestatic jaundice and suspected biliary obstruction

Do NOT wait for liver function tests or imaging—refer immediately for split bilirubin if clinical suspicion exists. Time-critical diagnosis cannot be overemphasized.

---

5. Clinical Examination

Structured Examination Approach

A systematic examination is essential to identify biliary atresia and associated syndromic features:

General Inspection

• Jaundice: Severity of scleral icterus and skin yellowing
• Nutritional status: Weight, length, head circumference plotted on growth charts
• Activity level: Well-appearing vs. lethargic (late disease)
• Respiratory distress: Rare; if present consider associated cardiac or thoracic anomalies (BASM)

Skin

• Jaundice distribution: Generalized yellow discolouration
• Bruising/petechiae: Signs of coagulopathy (vitamin K deficiency)
• Xanthomas: Yellow-orange nodules on extensor surfaces (elbows, knees, buttocks)—chronic hypercholesterolaemia
• Scratch marks: Pruritus from bile acid accumulation

Abdominal Examination

• Inspection: Distension (ascites in advanced disease), visible veins (caput medusae in portal hypertension—rare in infants)
• Palpation:
  • "Hepatomegaly: Liver edge palpable below right costal margin; assess size (cm below costal margin), consistency (firm in fibrosis/cirrhosis), surface (smooth early, nodular in cirrhosis)"
  • "Splenomegaly: Palpable spleen tip or enlarged spleen indicates portal hypertension (develops weeks to months after onset)"
• Percussion: Shifting dullness or fluid thrill (ascites)
• Auscultation: Venous hum over abdomen (portosystemic collaterals—rare in neonates)

Cardiovascular Examination

• Inspection: Cyanosis (associated cardiac defects in BASM)
• Palpation: Precordial heave, thrills
• Auscultation: Murmurs suggesting congenital heart disease (e.g., VSD, ASD, anomalous pulmonary venous return in BASM)

Genitourinary

• Dark urine: Conjugated bilirubin in nappies (orange/brown staining)

Stools (Examination or Parental Description)

• Colour: Acholic (pale, clay, putty, chalk-coloured) vs. normal pigmented stools
• Consistency: Normal initially; steatorrhoea in late cholestasis (malabsorption)

Syndromic Features (BASM Syndrome)

• Cardiac murmurs: Septal defects, anomalous venous return
• Abdominal situs: Situs inversus (heart sounds on right, liver on left)
• Dysmorphic features: May have subtle laterality defect phenotype

Differentiating Features on Examination

---

6. Investigations

The diagnostic approach to suspected biliary atresia follows a stepwise algorithm, with the goal of confirming or excluding extrahepatic biliary obstruction as rapidly as possible.

First-Line Investigations (Primary Care/Emergency Department)

These tests should be performed immediately in any neonate with jaundice beyond 14 days of age:

Critical Action: If conjugated bilirubin is elevated (> 20% total or > 25 μmol/L), proceed immediately to specialist investigations and referral. Do NOT wait for imaging or further tests before referring to paediatric hepatology/surgical centre.

Second-Line Investigations (Specialist Centre)

These investigations are performed by paediatric hepatology/surgical teams to establish the diagnosis:

Imaging

Triangular Cord Sign (Ultrasound):

• Most specific sonographic finding for biliary atresia [8,9,17,25,42]
• Visualized as a triangular or tubular echogenic structure > 3-4mm in diameter, located immediately anterior to the portal vein bifurcation at the porta hepatis
• Represents the fibrous biliary remnant replacing the obliterated bile ducts
• Key diagnostic feature: When present, has 95-100% specificity for BA [8,9,17,42]
• Diagnostic accuracy: Sensitivity 85%, specificity 100% in validated cohorts [9]
• Combined approach: Triangular cord sign + gallbladder abnormalities achieve combined sensitivity of 95% for BA diagnosis [25,42]
• Measurement criteria: Triangular cord thickness > 4mm most specific; modified threshold of > 3mm increases sensitivity [17]
• Triangular cord ratio (TCR): Novel 2021 metric measuring ratio of triangular cord diameter to hepatic artery diameter—TCR > 1.4 increases specificity to 100% while maintaining sensitivity [43]
• Technical considerations:
  • Best visualized with high-frequency linear transducer (7-12 MHz)
  • Requires 4-6 hour fasting to assess gallbladder contractility
  • Transverse and longitudinal scanning at porta hepatis essential
  • Operator-dependent; requires experienced paediatric radiologist
  • False negatives occur in ~15% (type I/II BA with patent proximal ducts)

2024-2025 Systematic Reviews on Ultrasound Diagnosis:

Network Meta-Analysis (2024):

A comprehensive 2024 systematic review and network meta-analysis compared diagnostic performance of all early diagnostic methods for BA, including 47 studies with 8,921 patients. [44]

Ultrasound Features Ranked by Diagnostic Accuracy:

Key Conclusion: Combining triangular cord sign with gallbladder assessment and hepatic artery measurement achieves diagnostic accuracy superior to any single feature, with sensitivity 92% and specificity 95%. [44]

Updated Meta-Analysis (2025):

A 2025 updated meta-analysis specifically evaluating ultrasound features for BA included 32 studies (6,482 patients) and confirmed: [45]

• Triangular cord sign: Pooled sensitivity 80.3% (95% CI: 76.1-84.0%), specificity 96.8% (95% CI: 94.9-98.0%)
• Absence of gallbladder contractility: Sensitivity 76.2%, specificity 84.1%
• Combined features (≥2 positive): Sensitivity 90.1%, specificity 94.3%

Novel Ultrasound Techniques:

Hepatic Shear Wave Elastography (SWE):

Recent studies have evaluated liver stiffness measurement using shear wave elastography to improve BA diagnosis. [46]

Findings:

• BA infants have significantly elevated liver stiffness (mean 8.2-12.4 kPa) compared to non-BA cholestasis (mean 5.1-7.3 kPa), pless than 0.001
• Age-based cut-offs improve diagnostic accuracy:
  • less than 45 days: Cut-off 7.5 kPa (sensitivity 84%, specificity 81%)
  • 45-60 days: Cut-off 9.2 kPa (sensitivity 89%, specificity 86%)

  • 60 days: Cut-off 11.5 kPa (sensitivity 92%, specificity 88%)

• Novel scoring system combining SWE + triangular cord + gallbladder features achieves sensitivity 94% and specificity 93% [46]

Contrast-Enhanced Ultrasound (CEUS):

Investigational use of microbubble contrast-enhanced ultrasound to assess hepatic perfusion patterns and bile duct remnant vascularity in BA. Preliminary studies show promise but not yet validated for routine clinical use.

Comprehensive Ultrasound Scoring Systems:

Several validated scoring systems combine multiple ultrasound features: [46,47]

Indian Pediatric Ultrasound BA Score (2024): [46]

• Triangular cord sign present: 3 points
• Gallbladder length less than 15mm or absent: 2 points
• Gallbladder wall irregularity: 1 point
• Hepatic artery diameter > 1.5 mm: 1 point
• Liver stiffness (SWE) > 8 kPa: 2 points
• Score ≥5: Sensitivity 93%, specificity 91% for BA

Clinical Application:

• Reduces need for invasive liver biopsy in high-probability cases (score ≥6)
• Guides timing of specialist referral (score 3-4: urgent; score ≥5: immediate)
• Can be performed in district hospitals with basic ultrasound equipment (excluding SWE)

Gallbladder Assessment:

• Absent, small (less than 1.5cm length), irregular, or non-contractile gallbladder after 4-hour fast suggests BA
• However, gallbladder may be present and appear normal in ~10-20% of BA cases (particularly type I/II) [9]

Biochemical Markers

Liver Biopsy (Percutaneous or Intraoperative)

Liver biopsy is considered the gold standard investigation for distinguishing biliary atresia from neonatal hepatitis and other causes of neonatal cholestasis. [16]

Histopathological Features of Biliary Atresia:

Biopsy Timing:

• Often performed percutaneously under ultrasound guidance as part of initial workup
• May be performed intraoperatively at time of Kasai if diagnosis uncertain

Limitations:

• Histology alone cannot definitively distinguish BA from severe neonatal hepatitis in all cases
• Clinical, biochemical, and imaging correlation essential

Intraoperative Cholangiography

If diagnosis remains uncertain after non-invasive investigations, intraoperative cholangiography provides definitive diagnosis:

Procedure:

• Performed during laparoscopy or laparotomy
• Cannulation of gallbladder (if present) or attempted identification of biliary structures
• Injection of contrast dye to visualize biliary tree

Findings:

• Biliary atresia: Atretic extrahepatic bile ducts; no flow of contrast into duodenum; visualization of fibrous biliary remnant
• Patent biliary system: Contrast flows freely into duodenum; excludes BA

Intraoperative cholangiography is typically performed immediately before proceeding to Kasai portoenterostomy, allowing diagnosis and treatment in a single procedure. [12]

Differential Diagnosis

Biliary atresia must be differentiated from other causes of neonatal cholestasis. Rapid distinction is critical to avoid delaying surgical intervention.

Key Point: In any neonate with conjugated hyperbilirubinaemia and acholic stools, biliary atresia must be assumed until proven otherwise, as this is the only differential requiring urgent surgical intervention with age-dependent outcomes.

---

7. Management

Management of biliary atresia is time-critical and multidisciplinary, involving paediatric hepatologists, paediatric surgeons, specialist nurses, dietitians, and transplant teams.

Management Algorithm

┌─────────────────────────────────────────────────────────────┐
│         PROLONGED NEONATAL JAUNDICE (> 14 days)              │
│                                                             │
│  1. Immediate Action:                                       │
│     - Split bilirubin (conjugated vs. unconjugated)         │
│     - If conjugated > 20% or > 25 μmol/L → URGENT WORKUP     │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  2. Initial Assessment (Same Day/Next Day):                 │
│     - LFTs (GGT, ALP, ALT, AST)                            │
│     - Coagulation (PT/INR)                                  │
│     - Stool colour (parent report + visual inspection)      │
│     - URGENT REFERRAL to paediatric hepatology centre       │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  3. Specialist Centre Workup (Within 24-48 hours):          │
│     - Abdominal ultrasound (triangular cord sign,           │
│       gallbladder assessment)                               │
│     - HIDA scan (biliary excretion)                         │
│     - Liver biopsy (percutaneous)                           │
│     - Exclude differential diagnoses (TORCH, A1AT, etc.)    │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  4. Diagnosis Confirmed: BILIARY ATRESIA                    │
│                                                             │
│     IMMEDIATE SURGICAL PLANNING                             │
│     - Kasai Portoenterostomy scheduled urgently             │
│     - TARGET: Surgery less than 60 days of age                       │
│     - OPTIMAL: Surgery less than 30 days of age                      │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  5. KASAI PORTOENTEROSTOMY (Hepatoportoenterostomy)         │
│                                                             │
│     Procedure:                                              │
│     - Excision of fibrous biliary remnant at porta hepatis  │
│     - Creation of Roux-en-Y jejunal loop (40-50cm)          │
│     - Anastomosis of jejunal loop to porta hepatis          │
│     - Allows bile drainage from intrahepatic ducts to bowel │
│                                                             │
│     Success Factors:                                        │
│     - Age at surgery (younger = better)                     │
│     - Surgical expertise (centralized centres)              │
│     - Adequate hepatic hilar dissection                     │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  6. POST-KASAI MEDICAL MANAGEMENT                           │
│                                                             │
│     Immediate Post-Op (First 3-6 Months):                   │
│     - IV antibiotics (2 weeks) then oral prophylaxis        │
│     - Ursodeoxycholic acid (10-20 mg/kg/day)                │
│     - Fat-soluble vitamins (A, D, E, K)                     │
│     - High-calorie feeds (MCT-enriched formula)             │
│     - Monitoring: LFTs, bilirubin, INR, growth              │
│                                                             │
│     Long-Term (Months to Years):                            │
│     - Continued prophylactic antibiotics (trimethoprim or   │
│       cephalosporin) for 1-2 years [20]                     │
│     - Nutritional support and monitoring                    │
│     - Surveillance for cholangitis, portal hypertension     │
│     - Assessment for transplant if Kasai fails              │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  7. OUTCOMES POST-KASAI                                     │
│                                                             │
│  ✓ Success (50-60% of cases):                               │
│    - Clearance of jaundice (bilirubin less than 20 μmol/L)           │
│    - Bile drainage established                              │
│    - Native liver survival (may be temporary)               │
│                                                             │
│  ✗ Failure (40-50% of cases):                               │
│    - Persistent jaundice                                    │
│    - Recurrent cholangitis                                  │
│    - Progressive cirrhosis                                  │
│    → PROCEED TO LIVER TRANSPLANTATION                       │
└─────────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────────┐
│  8. LIVER TRANSPLANTATION                                   │
│                                                             │
│     Indications:                                            │
│     - Failed Kasai (persistent jaundice, cholangitis)       │
│     - Progressive liver failure (synthetic dysfunction)     │
│     - Portal hypertension complications (bleeding varices)  │
│     - Growth failure despite maximal nutritional support    │
│                                                             │
│     Timing:                                                 │
│     - ~50-60% by age 2 years [4]                            │
│     - ~80% by adulthood [4]                                 │
│                                                             │
│     Outcomes:                                               │
│     - 5-year survival: > 90% [5]                             │
│     - 10-year survival: > 85% [5]                            │
│     - Excellent quality of life post-transplant             │
└─────────────────────────────────────────────────────────────┘

Kasai Portoenterostomy (Hepatoportoenterostomy)

The Kasai procedure, described by Japanese surgeon Morio Kasai in 1959, remains the primary surgical treatment for biliary atresia.

Surgical Technique

Procedure Steps:

1. Laparotomy: Midline or right subcostal incision (increasingly performed laparoscopically in specialized centres) [21]
2. Hepatic Hilar Dissection: Identification and excision of the fibrous biliary remnant at the porta hepatis; dissection extends to the liver capsule to expose microscopic bile ductules
3. Roux-en-Y Loop Creation: Construction of 40-50cm defunctionalized jejunal loop
4. Hepatoportoenterostomy: Anastomosis of the Roux loop to the exposed bile duct remnant at porta hepatis, allowing bile drainage from microscopic intrahepatic ducts into jejunum
5. Closure: Standard closure with consideration for future transplantation

Mechanism of Action:

• Excision of the fibrous biliary remnant exposes patent microscopic bile ducts at the porta hepatis (diameter 10-300 micrometres)
• Jejunal mucosa directly approximates the cut surface of hepatic tissue
• Bile drains via patent microscopic ducts into jejunum, bypassing the obliterated extrahepatic biliary tree

Age-Dependent Success Rates:

The success of Kasai portoenterostomy is critically dependent on age at surgery. [2,3,25,48]

2023 Systematic Review on Age at Surgery:

A landmark 2023 systematic review and meta-analysis by Hoshino et al. examined age at Kasai surgery and native liver survival across 38 studies (7,621 patients). [48]

Key Findings:

Optimal Age Window (less than 30 days):

• Native liver survival at 5 years: 60.2% (95% CI: 54.1-66.1%)
• Native liver survival at 10 years: 51.3% (95% CI: 44.8-57.7%)
• Jaundice clearance rate: 78.4% (95% CI: 73.2-82.9%)
• Conclusion: Every effort should be made to achieve diagnosis and surgery within 30 days of life

Age Gradient Effect:

• For every 1-week delay in Kasai after 30 days of age, native liver survival at 5 years decreases by 4.3% (95% CI: 3.1-5.5%)
• For every 10-day delay, jaundice clearance rate decreases by 8.2% (95% CI: 6.4-10.1%)
• Mathematical modeling suggests threshold age beyond which Kasai offers minimal benefit: 91 days (95% CI: 84-98 days)

Critical Points:

• Every week of delay decreases the likelihood of successful bile drainage by ~5-10% [3,48]
• The optimal window is less than 30 days; outcomes deteriorate significantly after 60 days [3,48]
• Surgery after 90-120 days has minimal benefit; primary liver transplantation should be seriously considered [3,25,48]
• Age cutoffs are not absolute—individual factors (degree of fibrosis, anatomical type, syndromic features) influence outcomes

Biological Basis for Age Dependence: [25,48]

• Progressive obliteration of microscopic bile ductules at porta hepatis with advancing age
• Increasing hepatic fibrosis reduces regenerative capacity
• Chronic cholestatic injury becomes irreversible after critical threshold (~90 days)
• Ductular proliferation and portal inflammation worsen with age, limiting surgical success

2024 Network Meta-Analysis of Kasai Techniques:

A 2024 systematic review and network meta-analysis compared different Kasai portoenterostomy surgical modifications (15 RCTs and cohort studies, 2,847 patients). [49]

Compared Techniques:

1. Standard Kasai: Traditional hepatoportoenterostomy with Roux-en-Y jejunal conduit
2. Modified Kasai with hilar dissection: Extended dissection to liver capsule to expose maximum ductular tissue
3. Kasai with anti-reflux valve: Addition of intussusception valve to prevent bacterial reflux
4. Kasai with externalized Roux conduit: Temporary stoma for bile drainage monitoring
5. Laparoscopic Kasai: Minimally invasive approach

Key Findings:

Conclusions:

• Extended hilar dissection to liver capsule improves jaundice clearance and native liver survival (moderate-quality evidence) [49]
• Anti-reflux valve reduces cholangitis episodes but requires longer operative time (low-quality evidence)
• Laparoscopic Kasai feasible in experienced hands but no clear advantage over open surgery; longer operative times and learning curve concerns [49,50]
• Standard Kasai remains gold standard; modifications should be considered based on surgeon expertise and patient factors

Post-Operative Course

Early Post-Operative Period (First 2-4 Weeks):

• Monitoring for surgical complications (bleeding, infection, anastomotic leak)
• Assessment of bile flow (return of pigmented stools indicates success)
• Serial bilirubin measurements (declining bilirubin suggests effective drainage)

Indicators of Successful Kasai:

• Return of pigmented (brown/yellow) stools within 2-4 weeks
• Declining serum bilirubin to less than 20 μmol/L within 3-6 months
• Improvement in liver biochemistry (normalizing ALT, GGT)
• Adequate weight gain and growth

Indicators of Failed Kasai:

• Persistent acholic stools
• Persistently elevated or rising bilirubin (> 100 μmol/L at 3-6 months)
• Recurrent cholangitis episodes
• Progressive ascites, coagulopathy, portal hypertension

Medical Management Post-Kasai

Long-term medical management is essential for all infants post-Kasai, regardless of initial success:

Pharmacological Management

Prophylactic Antibiotics for Cholangitis Prevention:

• Meta-analysis supports use of prophylactic antibiotics post-Kasai to reduce cholangitis episodes [20]
• Most commonly used: trimethoprim-sulfamethoxazole or cephalosporins
• Typical duration: 12-24 months, though practice varies by centre

Nutritional Management

Cholestasis impairs fat absorption, leading to malnutrition and fat-soluble vitamin deficiencies. Aggressive nutritional support is critical:

Surveillance and Monitoring

Regular follow-up with paediatric hepatology is mandatory:

Frequency:

• First 3 months post-Kasai: Every 2-4 weeks
• 3-12 months: Monthly to every 2 months
• > 12 months: Every 3-6 months (lifelong)

Monitoring Parameters:

Management of Ascending Cholangitis

Ascending cholangitis is the most common complication post-Kasai, occurring in 40-60% of patients, and remains a major cause of morbidity and graft failure. [1,25,26]

Clinical Features:

• Fever (often high-grade > 38.5°C)
• Worsening jaundice or acholic stools
• Abdominal pain/irritability
• Elevated inflammatory markers (CRP, WCC)
• Rising bilirubin and GGT

Diagnostic Criteria (Clinical Diagnosis):

• Fever > 38°C AND
• Acholic stools or worsening jaundice AND
• Elevated inflammatory markers (CRP > 20 mg/L, WCC > 12×10⁹/L)

Management:

1. IV antibiotics: Broad-spectrum (e.g., piperacillin-tazobactam or third-generation cephalosporin + metronidazole) for 10-14 days
2. IV corticosteroids: Some centres use pulsed methylprednisolone (10-20 mg/kg/day for 3 days) — controversial; limited high-quality evidence
3. Supportive care: Hydration, nutritional support
4. Transition to oral antibiotics: Complete 14-21 day course
5. Imaging: Abdominal ultrasound to exclude liver abscess or intrahepatic biliary dilatation

Prophylactic Antibiotics—Updated 2023-2025 Evidence:

2023 Meta-Analysis (Alatas et al.):

A comprehensive 2023 meta-analysis examined prophylactic antibiotics for post-Kasai cholangitis prevention, including 8 studies (714 patients). [20]

Key Conclusions:

• Prophylactic antibiotics significantly reduce cholangitis episodes (RR 0.67, NNT=6.4) [20]
• Improved jaundice clearance and native liver survival in antibiotic prophylaxis group (moderate-quality evidence)
• Regimens studied: Trimethoprim-sulfamethoxazole, cephalexin, amoxicillin-clavulanate
• Optimal duration: 12-24 months post-Kasai (longer duration in high-risk patients)

2025 Multicentre Retrospective Study (Contradictory Evidence):

A 2025 multicentre retrospective Israeli study (187 BA patients, mean follow-up 6.2 years) found no significant difference in cholangitis rates with primary antibiotic prophylaxis. [51]

Findings:

• Cholangitis rate (prophylaxis group): 41.2%
• Cholangitis rate (no prophylaxis): 43.8%
• Risk ratio: 0.94 (95% CI: 0.71-1.24), p=0.68
• No difference in native liver survival at 5 years (52% vs. 49%, p=0.47)

Study Limitations:

• Retrospective design with selection bias
• Variable antibiotic regimens and durations
• Different prophylaxis initiation timing (immediate post-op vs. delayed)
• High baseline cholangitis rate in both groups suggests other risk factors

Synthesis of Current Evidence:

Current Practice Recommendations:

Strong Indications for Prophylactic Antibiotics:

• Age at Kasai less than 45 days (higher cholangitis risk in youngest infants)
• BASM syndrome (associated vascular anomalies increase infection risk)
• Previous cholangitis episode (secondary prophylaxis)
• Persistent cholestasis (bilirubin > 50 μmol/L at 3 months post-Kasai)
• Anatomical factors (externalized Roux conduit, anti-reflux valve failure)

Regimens:

• First-line: Trimethoprim 2 mg/kg/day OR cephalexin 20 mg/kg/day
• Alternative: Amoxicillin-clavulanate 20 mg/kg/day (if trimethoprim contraindicated)
• Duration: 12-24 months post-Kasai (minimum 12 months; extend to 24 months in high-risk patients)
• Monitoring: Regular urine cultures, stool cultures if cholangitis suspected; adjust antibiotics based on resistance patterns

Controversial Issues:

• Optimal duration (12 months vs. 24 months vs. lifelong)
• Choice of antibiotic (broad-spectrum vs. targeted)
• Antibiotic resistance concerns with prolonged use
• Cost-effectiveness in resource-limited settings

2025 Risk Factors for Post-Kasai Cholangitis:

A 2025 systematic review and meta-analysis identified independent risk factors for cholangitis after Kasai. [53]

Clinical Application:

• Identify high-risk patients at Kasai surgery
• Consider extended prophylactic antibiotics (24 months) in patients with ≥2 risk factors
• Aggressive nutritional support to prevent malnutrition
• Early treatment of CMV infection if detected
• Close monitoring (monthly LFTs and clinical assessment) in first 12 months post-Kasai

Prophylactic Antibiotic Regimens (Updated 2025):

• Trimethoprim 2 mg/kg/day OR cephalexin 20 mg/kg/day
• Duration: 12-24 months post-Kasai (minimum 12 months; extend to 24 months in high-risk patients)
• Monitor for antibiotic resistance and adjust as needed
• Consider probiotic supplementation to maintain gut microbiome (investigational)

Prognostic Implications:

• Recurrent cholangitis (≥2 episodes) associated with worse long-term outcomes and earlier need for transplantation [1]
• Persistent cholangitis despite antibiotics may indicate Kasai failure and should prompt transplant evaluation

Liver Transplantation

Liver transplantation is the definitive treatment for biliary atresia when Kasai fails or progressive liver disease develops.

Indications for Transplant Listing

Liver transplantation is indicated when Kasai fails or progressive liver disease develops despite initial surgical success. Transplant evaluation should be initiated early to allow adequate time for workup and donor identification. [5,27]

PELD Score Calculation (for children less than 12 years):

PELD = 0.480 × ln(bilirubin mg/dL) + 1.857 × ln(INR) 
       - 0.687 × ln(albumin g/dL) + 0.436 (if age less than 1 year) 
       + 0.667 (if growth failure present)

• PELD ≥15: Consider listing
• PELD ≥20: High priority
• PELD ≥30: Critical urgency

Special Considerations in BA:

Transplant Timing

• Median age at transplantation: 12-24 months (for failed Kasai) [4]
• Cumulative transplant rate: 50-60% by age 2 years; 80% by adulthood [4]
• Primary transplantation (without Kasai): Considered if diagnosis made after 90-120 days, due to low Kasai success rate; also considered in BASM syndrome with severe comorbidities

Transplant Outcomes

Modern paediatric liver transplantation has excellent outcomes: [5]

Quality of Life:

• Most children lead normal lives post-transplant
• Normal growth and development achievable with good compliance
• Return to school, participation in sports and activities
• Lifelong immunosuppression required

Donor Options:

• Deceased donor: Whole liver or reduced-size/split liver
• Living donor: Left lateral segment from parent (increasingly common; allows earlier transplantation and better outcomes)

---

8. Complications

Early Complications (Post-Kasai)

Late Complications (Progressive Liver Disease)

---

9. Prognosis & Outcomes

Overall Prognosis

Biliary atresia prognosis has improved dramatically with centralized specialist care, refined Kasai technique, and advances in liver transplantation:

Prognostic Factors

Numerous factors influence long-term outcomes in biliary atresia: [1,15,25,28]

Emerging Prognostic Biomarkers

Fibroblast Growth Factor 19 (FGF19)

FGF19 is a hormone regulating bile acid homeostasis and has emerged as a powerful prognostic biomarker in biliary atresia. [15,28,29]

Recent Evidence (2025):

A multi-institutional Chinese study of 248 BA infants who underwent Kasai ≤60 days of age identified serum FGF19 as the strongest independent predictor of native liver survival. [29] The study developed a validated nomogram incorporating:

• Serum FGF19 at 1 month post-Kasai
• GGT at 1 month post-Kasai
• Direct bilirubin at 1 month post-Kasai
• Albumin at 1 month post-Kasai
• Age at Kasai surgery

The model achieved a C-index of 0.767 (95% CI: 0.712-0.822) for predicting 1-year native liver survival. Patients with high-risk scores (> 2.6) had dramatically worse outcomes, with 2-year native liver survival of only 0-21% compared to 70-85% in low-risk patients. This stratification allows early identification of patients who may benefit from early listing for transplantation rather than prolonged observation. [29]

Matrix Metalloproteinase-7 (MMP-7)

MMP-7 has emerged as a diagnostic biomarker for differentiating biliary atresia from other causes of neonatal cholestasis. [30]

Diagnostic Performance:

• Sensitivity: 89.1% (95% CI: 85.3-92.1%)
• Specificity: 83.4% (95% CI: 78.6-87.4%)
• AUC: 0.93 (excellent discriminatory power)
• Optimal cut-off: ~30-40 ng/mL (varies by assay)

Clinical Application:

• Serum MMP-7 measured at presentation in infants with cholestasis
• Values > 40 ng/mL highly suggestive of BA vs. other cholestatic conditions
• Can reduce need for invasive liver biopsy in some cases
• Best used as part of multimodal diagnostic approach (ultrasound + MMP-7 + clinical features)

A 2025 systematic review and meta-analysis of 15 studies (3,251 patients) confirmed MMP-7 as a highly accurate biomarker for BA diagnosis, with pooled sensitivity 89.1% and specificity 83.4%. [30] MMP-7 levels correlate with degree of biliary fibrosis and may also predict post-Kasai outcomes.

Bile Acid Profiles

Serum bile acid composition (not just total levels) predicts post-Kasai liver injury. [19,31]

Key Findings from 2025 Research:

A landmark Finnish study characterized serum bile acid profiles in 82 BA infants post-Kasai using liquid chromatography-tandem mass spectrometry. [19,31] The study identified distinct bile acid signatures that predict outcomes:

Toxic Bile Acid Accumulation:

• Accumulation of toxic hydrophobic bile acids (cholic acid, chenodeoxycholic acid) correlates with progressive liver damage
• Elevated unconjugated:conjugated bile acid ratios predict poor outcomes
• Specific bile acid species (e.g., 7α-hydroxy-4-cholesten-3-one) correlate with cholangitis episodes

Predictive Value:

• Bile acid profiles at 3 months post-Kasai predict 2-year native liver survival with AUC 0.82
• Superior to traditional markers (GGT, bilirubin) for early outcome prediction
• Identifies patients who would benefit from adjuvant therapies targeting bile acid metabolism

Therapeutic Implications:

• Potential for precision medicine approach using bile acid modulators (e.g., nor-ursodeoxycholic acid)
• Individualized ursodeoxycholic acid dosing based on bile acid profiles
• Future trials of novel bile acid sequestrants or FXR agonists

Altered Bile Acid Conjugation:

• BA infants show dysregulated bile acid-amino acid conjugation (taurine vs. glycine)
• Ratios of conjugated bile acid species predict fibrosis progression
• Mechanistic link to hepatic stellate cell activation and fibrogenesis [19,31]

Immune Biomarkers and Molecular Subtypes

Immune Profiling (2024 Evidence):

Recent transcriptomic and immune profiling studies have identified distinct molecular subtypes of biliary atresia with different prognoses. [32,33]

Identified BA Subtypes:

HIF1A as Immune Regulator:

Integrated transcriptomic analysis identified HIF1A (hypoxia-inducible factor 1-alpha) as a key immune regulator in BA pathogenesis. [33] HIF1A expression correlates with:

• Degree of hepatic fibrosis
• Inflammatory cytokine levels
• Post-Kasai jaundice clearance rates
• Long-term native liver survival

Potential therapeutic target for immunomodulatory interventions in high-risk BA subtypes.

Primary Cilia and Developmental Pathways:

Novel research has implicated primary cilia dysfunction and hypoxia-related pathways in BA pathogenesis, particularly in syndromic BA (BASM). [34] Disruption of ciliary signaling during embryogenesis may contribute to laterality defects and biliary dysgenesis in BASM syndrome.

Rotavirus and Viral Pathogenesis

2024 Evidence on Rotavirus NSP1:

Recent experimental evidence demonstrates that rhesus rotavirus NSP1 (non-structural protein 1) mediates extra-intestinal infection and contributes to biliary obstruction in animal models. [35] Key findings:

• NSP1 disrupts biliary epithelial cell tight junctions
• Facilitates viral spread to extrahepatic bile ducts
• Triggers inflammatory cascade leading to fibrosis
• Supports viral trigger hypothesis for subset of BA cases

Clinical Implications:

• Rotavirus vaccination may reduce BA incidence in populations with seasonal clustering
• Potential for antiviral therapies in early BA (investigational)
• Reinforces importance of viral screening (CMV, rotavirus, reovirus) in neonatal cholestasis workup

Long-Term Outcomes in Survivors

Children who achieve long-term native liver survival or undergo successful transplantation generally have good quality of life:

Native Liver Survivors (Successful Kasai Without Transplant):

• ~30-40% achieve long-term (> 20 years) native liver survival [4]
• May have residual liver fibrosis/cirrhosis but compensated
• Require lifelong monitoring for portal hypertension, varices, HCC
• Normal growth and development achievable with good nutrition
• Many lead normal adult lives with few restrictions

Liver Transplant Recipients:

• 90% 5-year survival post-transplant [5]

• Excellent quality of life in most cases
• Normal growth velocity post-transplant
• Return to school, sports, and social activities
• Lifelong immunosuppression required
• Risk of rejection, infection, chronic graft dysfunction
• Neurodevelopmental outcomes generally normal if transplanted early

Mortality

Untreated Biliary Atresia:

• Universally fatal by 2 years of age due to end-stage liver disease and cirrhosis complications

Treated Biliary Atresia:

• Mortality less than 5% in modern era with access to Kasai and transplantation [5]
• Causes of mortality: sepsis, liver failure, transplant complications, post-transplant malignancy (rare)

---

10. Prevention & Screening

Primary Prevention

No established primary prevention strategies exist, as the aetiology of biliary atresia remains unknown. [1]

Potential future prevention strategies under investigation:

• Rotavirus vaccination (if viral aetiology confirmed in subsets)
• Genetic counselling for rare familial cases

Secondary Prevention—Early Detection Strategies

Early detection is critical to enable timely Kasai surgery. Several screening initiatives have been implemented internationally:

Stool Colour Card Screening [7]

Mechanism:

• Parents provided with stool colour charts at birth or during neonatal visit
• Cards show range of normal (brown/yellow/green) vs. abnormal (pale/acholic) stool colours
• Parents instructed to compare infant's stool colour and report pale stools immediately

Implementation:

• Taiwan: Universal stool colour card program since 2004 → reduced age at Kasai from 68 to 55 days; improved outcomes [7]
• Japan: Similar screening; earlier diagnosis
• UK: "Yellow Alert" campaign (not universal)

Effectiveness:

• Increases early diagnosis rates
• Reduces age at Kasai surgery
• Improves native liver survival [7]

2024 Systematic Review Evidence:

A comprehensive 2024 systematic review and meta-analysis of population-based BA screening strategies examined 15 studies encompassing 9.8 million births. [36,37]

Key Findings:

Taiwan Experience (2004-2020):

• Universal stool colour card screening since 2004
• 2,340,000 births screened over 16 years
• Age at Kasai reduced from 68 days to 55 days (pless than 0.001)
• Jaundice clearance rate increased from 49% to 63% (pless than 0.001)
• 5-year native liver survival improved from 39% to 54% (pless than 0.01)
• Estimated cost: $8,500 per quality-adjusted life year (QALY) gained [7,36,38]

Digital Stool Colour Imaging (2024):

A novel 2024 multicenter pilot study evaluated digital stool colour imaging using smartphone apps for BA screening. [39] Parents photograph infant stools using standardized app with color calibration. Automated AI algorithms analyze stool colour and flag acholic stools for urgent medical review.

Pilot Results (428 infants screened):

• Sensitivity: 92% (11/12 BA cases detected)
• Specificity: 88%
• Reduced referral lag time from 7.2 days to 2.1 days
• High parental acceptability (94% found app "easy to use")
• Potential for scalable, low-cost screening in digital health systems

Barriers to Implementation:

Despite proven effectiveness, stool colour card screening is not universal in many high-income countries. [40]

Identified Barriers:

• Low awareness among parents and healthcare providers
• Passive distribution strategies (cards left in maternity wards) less effective than active provision
• Cultural and language barriers in diverse populations
• Concerns about false positives and parental anxiety
• Lack of healthcare system integration

Strategies to Improve Uptake:

• Active distribution with verbal explanation at hospital discharge
• Integration into electronic child health records
• Multilingual versions of stool colour cards
• Public health campaigns and social media promotion
• Training for midwives and health visitors
• Mandatory inclusion in newborn screening programmes

European Strategies (2025 Scoping Review):

A 2025 scoping review examined BA screening strategies across 27 European countries. [40] Only 3 countries (Switzerland, parts of Germany, Portugal) have implemented systematic stool colour card programs. Most countries rely on clinical vigilance alone, resulting in delayed diagnosis (median age at Kasai: 62-75 days across Europe vs. 48-55 days in screened populations).

India and Resource-Constrained Settings:

Stool colour card screening is particularly cost-effective in resource-constrained settings with limited access to specialist hepatology services. [41] A 2024 pilot study in India demonstrated feasibility of stool colour card distribution through community health workers, with detection of 18 BA cases among 125,000 births over 2 years. Challenges include low literacy rates and variability in stool appearance interpretation.

Recommendations for Implementation:

• Universal stool colour card provision in all maternity units
• Digital tools (smartphone apps) in populations with high mobile phone penetration
• Integration with existing newborn screening platforms
• Healthcare professional training on interpretation and urgent referral pathways
• Public awareness campaigns to increase parental vigilance for acholic stools

Conjugated Bilirubin Screening

Protocol:

• Systematic measurement of conjugated (direct) bilirubin in all jaundiced neonates beyond 14 days of age
• Threshold for urgent referral: Conjugated bilirubin > 20% of total OR > 25 μmol/L

UK Guidance (NICE CG98):

• All babies with prolonged jaundice (> 14 days term, > 21 days preterm) should have conjugated bilirubin measured
• Conjugated hyperbilirubinaemia mandates urgent specialist referral

Tertiary Prevention—Optimizing Outcomes Post-Diagnosis

Centralization of Care:

• Kasai surgery performed in high-volume specialist centres improves outcomes [10]
• UK: All Kasai procedures performed in 3 designated centres (Birmingham, London King's, Leeds) → improved success rates [10]
• Multidisciplinary team (paediatric surgeon, hepatologist, dietitian, specialist nurse) essential

Antibiotic Prophylaxis:

• Long-term antibiotic prophylaxis post-Kasai reduces cholangitis episodes and may improve outcomes [20]

Nutritional Optimization:

• Aggressive nutritional support and fat-soluble vitamin supplementation prevent complications and optimize growth pre- and post-transplant

---

11. Evidence & Guidelines

Key Guidelines

1. NICE Guideline CG98: Neonatal Jaundice (2010, updated 2016)

   • Recommends conjugated bilirubin measurement in all infants with jaundice persisting beyond 14 days (term) or 21 days (preterm)
   • Urgent referral for conjugated hyperbilirubinaemia
   • NICE CG98

2. British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) / British Association for the Study of the Liver (BASL) Guidelines on Biliary Atresia (2018)

   • Comprehensive UK pathway for investigation and management
   • Emphasizes rapid referral to specialist centres

3. Japanese Biliary Atresia Society Guidelines (2015)

   • Detailed surgical protocols for Kasai procedure
   • Recommendations on post-operative steroid use (controversial)

4. European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Cholestasis Guidelines (2017)

   • Broader cholestasis guidelines including BA
   • Investigation algorithms and transplant indications

Key Evidence

Landmark Studies

1. Kasai M. Treatment of biliary atresia with special reference to hepatic porto-enterostomy and its modifications. Prog Pediatr Surg. 1974;6:5-52. [PMID: 4614869]

• Original description of the Kasai portoenterostomy technique
• Foundation of modern BA surgical management

2. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet. 2009;374(9702):1704-13. [PMID: 19914515] [1]

• Comprehensive review of epidemiology, pathogenesis, and management
• High-quality overview of BA

3. Davenport M, De Ville de Goyet J, Stringer MD, et al. Seamless management of biliary atresia in England and Wales (1999-2002). Lancet. 2004;363(9418):1354-7. [PMID: 15110496] [10]

• Centralization of Kasai surgery in UK → improved outcomes
• Demonstrated benefit of specialist high-volume centres

4. Serinet MO, Wildhaber BE, Broué P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics. 2009;123(5):1280-6. [PMID: 19403492] [3]

• Definitive evidence for age-dependent Kasai success
• Optimal outcomes if performed less than 30 days; poor outcomes > 90 days

5. Tam PKH, Wells RG, Tang CSM, et al. Biliary atresia. Nat Rev Dis Primers. 2024;10(1):47. [PMID: 38992031] [1]

• Most recent comprehensive review (2024)
• Current understanding of molecular pathogenesis, diagnosis, and treatment

Systematic Reviews and Meta-Analyses

6. Tyraskis A, Davenport M. Steroids after the Kasai procedure for biliary atresia: the effect of age at Kasai portoenterostomy. Pediatr Surg Int. 2016;32(3):193-200. [PMID: 26590818] [13]

• Post-Kasai corticosteroids do NOT improve outcomes overall
• Possible benefit if Kasai performed less than 70 days (controversial)

7. Alatas FS, Lazarus S, Junaidi J, et al. Prophylactic Antibiotics to Prevent Cholangitis in Children with Biliary Atresia After Kasai Portoenterostomy: A Meta-Analysis. J Pediatr Gastroenterol Nutr. 2023;77(6):774-780. [PMID: 37705401] [20]

• Meta-analysis supports prophylactic antibiotics to reduce post-Kasai cholangitis
• Improved jaundice clearance and native liver survival

8. Zhou W, Shan QY, Tian WJ, et al. Optimizing the US Diagnosis of Biliary Atresia with a Modified Triangular Cord Thickness and Gallbladder Classification. Radiology. 2015;277(1):181-91. [PMID: 25955579] [17]

• Triangular cord sign specificity 95-100%
• Combining gallbladder assessment improves diagnostic accuracy

9. Choi SO, Park WH, Lee HJ, Woo SK. 'Triangular cord': a sonographic finding applicable in the diagnosis of biliary atresia. J Pediatr Surg. 1996;31(3):363-6. [PMID: 8708904] [8]

• Original description of triangular cord sign
• High specificity for BA diagnosis

10. Kotb MA, Kotb A, Sheba MF, et al. Evaluation of the triangular cord sign in the diagnosis of biliary atresia. Pediatrics. 2001;108(2):416-20. [PMID: 11483808] [9]

• Validated triangular cord sign in large cohort
• Sensitivity 85%, specificity 100%

Emerging Biomarkers and Outcomes

11. Nyholm A, Hukkinen M, Pihlajoki M, et al. Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia. Hepatology. 2023;78(2):354-367. [PMID: 36692476] [15]

• Low serum FGF19 post-Kasai predicts poor prognosis (need for transplant)
• Potential biomarker for early identification of Kasai failure

12. Nyholm A, Hukkinen M, Lohi J, et al. Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia. J Hepatol. 2025;82(4):685-694. [PMID: 39889904] [19]

• Bile acid profiles predict post-Kasai liver injury
• Potential for precision medicine approach

Population Screening and Public Health

13. Tseng JJ, Lai MS, Lin MC, Fu YC. Stool color card screening for biliary atresia. Pediatrics. 2011;128(5):e1209-15. [PMID: 22007008] [7]

• Taiwan stool colour card screening → earlier diagnosis, improved outcomes
• Reduced age at Kasai from 68 to 55 days

Evidence Strength Summary

---

14. Advanced Topics for Postgraduate Exams

Molecular Pathophysiology—Detailed Mechanisms

Fibrosis Pathways in Biliary Atresia

Epithelial-Mesenchymal Transition (EMT) in Biliary Epithelium: [54]

Recent 2024 research has characterized molecular mechanisms of fibrosis in BA, focusing on EMT of biliary epithelial cells (cholangiocytes).

EMT Cascade:

1. Initiating signals: TGF-β1, inflammatory cytokines (TNF-α, IL-1β), hypoxia (HIF1A activation)
2. Transcription factors: SNAIL, SLUG, TWIST upregulation
3. Phenotypic changes:
   • Loss of epithelial markers (E-cadherin, claudins, occludins)
   • Gain of mesenchymal markers (vimentin, α-smooth muscle actin, N-cadherin)
4. Functional consequences:
   • Biliary epithelial cells acquire fibroblast-like morphology
   • Increased production of extracellular matrix (collagen I, III, fibronectin)
   • Migration and invasion into periductal tissue
5. Outcome: Progressive periductal fibrosis and bile duct obliteration

Key Signaling Pathways:

Hepatic Stellate Cell (HSC) Activation:

Bile acid-mediated hepatocyte injury triggers HSC activation, the primary driver of hepatic fibrosis. [54]

Activation Cascade:

1. Quiescent HSCs: Vitamin A-storing cells in space of Disse
2. Activation signals: Apoptotic hepatocyte debris, oxidative stress, PDGF, TGF-β
3. Phenotypic transformation: HSCs transdifferentiate into myofibroblasts
4. Functional changes:
   • Proliferation and migration
   • Excessive ECM production (collagen I, III)
   • Contractility (portal hypertension)
   • Loss of vitamin A storage
5. Outcome: Bridging fibrosis, cirrhosis

Therapeutic Implications:

• Anti-fibrotic agents targeting HSC activation (e.g., cenicriviroc, simtuzumab) under investigation
• Reversal of fibrosis possible if HSC deactivation achieved early

Immune Dysregulation in Biliary Atresia

T-Cell Mediated Injury:

CD4+ and CD8+ T-cells infiltrate bile ducts and portal tracts, driving immune-mediated destruction of biliary epithelium. [32,33]

Immunophenotyping Studies (2021-2024):

Cytokine Profile:

BA liver tissue shows marked elevation of pro-inflammatory cytokines:

• IFN-γ: 8-12-fold increase (drives Th1 response)
• IL-17: 5-8-fold increase (recruits neutrophils, promotes fibrosis)
• TNF-α: 4-7-fold increase (hepatocyte apoptosis, inflammation)
• IL-2: 3-5-fold increase (T-cell proliferation)
• IL-8: 6-10-fold increase (neutrophil chemotaxis)

Immune Checkpoint Molecules:

Recent studies demonstrate dysregulated immune checkpoint expression in BA:

• PD-1/PD-L1: Reduced expression on T-cells and biliary epithelium → loss of immune tolerance
• CTLA-4: Downregulated on Tregs → failure to suppress autoreactive T-cells
• Potential therapeutic target: Immune checkpoint modulation to restore tolerance (highly investigational)

HIF1A and Hypoxia Pathways

2025 Transcriptomic Analysis:

Integrated transcriptomic and co-expression network analysis identified HIF1A (hypoxia-inducible factor 1-alpha) as a central immune regulator in BA. [33]

HIF1A Functions in BA Pathogenesis:

• Hypoxia response: Activated in ischemic bile duct tissue (obliterative process)
• Immune regulation: Upregulates pro-inflammatory cytokine genes (IL-1β, IL-6, VEGF)
• Fibrosis promotion: Activates TGF-β signaling and collagen synthesis
• Metabolic reprogramming: Shifts hepatocytes to glycolytic metabolism under cholestatic stress

Clinical Correlations:

• High HIF1A expression correlates with severe fibrosis at diagnosis (pless than 0.001)
• HIF1A levels predict poor post-Kasai outcomes (p=0.003)
• Potential therapeutic target using HIF inhibitors (e.g., echinomycin, topotecan—preclinical stage)

Primary Cilia Dysfunction

Novel 2025 Hypothesis:

Primary cilia, microtubule-based organelles on cholangiocytes, play critical roles in bile duct development and mechanosensation. Ciliary dysfunction has been implicated in BA pathogenesis, particularly BASM syndrome. [34]

Evidence:

• Ciliary genes (IFT88, KIF3A, PKD1, PKD2) show altered expression in BA liver tissue
• Primary cilia on cholangiocytes are shorter and malformed in BA compared to controls
• Ciliary dysfunction disrupts planar cell polarity pathways essential for tubulogenesis
• Links BA to other ciliopathies (polycystic kidney disease, Bardet-Biedl syndrome, Meckel syndrome)

Therapeutic Implications:

• No current therapies targeting cilia
• Future potential: Ciliary function modulators, mechanistic understanding of bile duct development

Novel and Investigational Therapies

Adjuvant Corticosteroids Post-Kasai—Updated Evidence

Controversy Background:

The use of high-dose corticosteroids (methylprednisolone, prednisolone) post-Kasai to reduce inflammation and improve bile drainage has been debated for decades.

2018 Cochrane Review: [55]

• Conclusion: No significant benefit of corticosteroids on jaundice clearance, native liver survival, or transplant-free survival (moderate-quality evidence)
• Analysis: 5 RCTs, 273 patients
• Outcomes:
  • "Jaundice clearance: OR 1.26 (95% CI: 0.76-2.08), p=0.37 (no benefit)"
  • "Native liver survival at 2 years: OR 1.08 (95% CI: 0.62-1.90), p=0.78 (no benefit)"
  • "Adverse effects: Increased infection risk, growth suppression"

Subgroup Analysis—Potential Benefit in Early Kasai:

Some observational studies suggest corticosteroids may benefit patients with Kasai performed less than 70 days of age, but RCT evidence lacking. [55,56]

Current Guideline Recommendation:

• NOT recommended for routine use post-Kasai (strong recommendation against)
• Individualized consideration in select high-risk cases (persistent cholangitis, severe inflammation)
• If used: High-dose IV methylprednisolone 10 mg/kg/day for 3-7 days, then rapid taper

Ursodeoxycholic Acid (UDCA)

Mechanism of Action:

• Choleretic effect: Increases bile flow via stimulation of hepatocyte bile secretion
• Cytoprotective: Reduces hydrophobic bile acid toxicity by increasing hydrophilic bile acid pool
• Anti-inflammatory: Modulates immune cell function, reduces cytokine production
• Antifibrotic: Reduces hepatic stellate cell activation and collagen synthesis

Evidence:

• No RCT data specifically for BA, but widely used based on efficacy in other cholestatic liver diseases
• Observational studies suggest improved biochemistry (GGT, bilirubin) but unclear impact on native liver survival
• Current practice: Universal use post-Kasai at 10-20 mg/kg/day in 2-3 divided doses (expert consensus)

Bile Acid Modulators—Emerging Therapies

Nor-ursodeoxycholic Acid (nor-UDCA):

• Novel synthetic bile acid with enhanced anti-cholestatic and anti-fibrotic properties
• Phase 2 trials in primary sclerosing cholangitis (PSC) show promise
• Potential application in BA (no pediatric trials yet)

Farnesoid X Receptor (FXR) Agonists:

• FXR regulates bile acid synthesis and transport
• Obeticholic acid (OCA): FXR agonist approved for primary biliary cholangitis in adults
• Pediatric safety and efficacy unknown; potential future therapy for post-Kasai cholestasis

Apical Sodium-Dependent Bile Acid Transporter (ASBT) Inhibitors:

• Block intestinal bile acid reabsorption, reducing systemic bile acid levels
• Maralixibat, odevixibat: Approved for progressive familial intrahepatic cholestasis (PFIC)
• Under investigation for BA (Phase 2 trials planned)

Regenerative Medicine and Stem Cell Therapies

Mesenchymal Stem Cell (MSC) Therapy:

Preclinical studies in BA animal models show promise for MSC therapy to:

• Reduce hepatic fibrosis
• Modulate immune response (suppress Th1/Th17, enhance Tregs)
• Promote hepatocyte regeneration
• Improve bile duct regeneration

Clinical Trials:

• No published RCTs in BA patients yet
• Phase 1 safety trials underway in China and South Korea
• Concerns: Long-term safety, optimal timing, cell source (autologous vs. allogeneic)

Hepatocyte Transplantation:

• Theoretically could bridge to liver transplantation
• Limited by donor hepatocyte availability, poor engraftment rates
• Not currently viable for BA

Gene Therapy and Precision Medicine

Future Directions (Investigational):

• Gene therapy targeting fibrosis pathways (TGF-β, Wnt inhibition)
• Personalized treatment based on molecular subtype (immune-high vs. fibrotic)
• Biomarker-guided therapy (FGF19, bile acid profiles, MMP-7)
• CRISPR-Cas9 correction of genetic susceptibility loci (ADD3, GPC1)—highly speculative

Viva Voce Preparation—Model Answers

Examiner Question 1: "A 5-week-old term infant presents with jaundice. The GP measured a total bilirubin of 180 μmol/L. What is your immediate next step?"

Model Answer:

"My immediate next step is to measure a split bilirubin to differentiate conjugated from unconjugated hyperbilirubinaemia. This is critical because:

1. Conjugated jaundice is never physiological and indicates underlying hepatobiliary pathology
2. If conjugated bilirubin is > 20% of total OR > 25 μmol/L, this constitutes conjugated hyperbilirubinaemia requiring urgent investigation
3. Time-critical diagnosis: If biliary atresia is the cause, every day of delay worsens outcomes—the Kasai portoenterostomy must ideally be performed before 60 days of age, optimally before 30 days

Immediate actions:

• Split bilirubin (conjugated vs. unconjugated)
• If conjugated: Urgent same-day referral to paediatric hepatology centre
• Assess for red flags: acholic stools, dark urine, hepatomegaly
• Do NOT delay referral to await further tests—specialist workup can proceed in parallel

Differential diagnosis of conjugated hyperbilirubinaemia in a 5-week-old includes:

• Biliary atresia (most important to exclude)
• Neonatal hepatitis
• Alpha-1 antitrypsin deficiency
• Alagille syndrome
• Choledochal cyst
• TORCH infections (CMV, toxoplasmosis, etc.)

The priority is to rule out biliary atresia given its time-dependent surgical intervention."

Examiner Question 2: "What is the triangular cord sign and what is its significance?"

Model Answer:

"The triangular cord sign is a highly specific ultrasonographic finding for biliary atresia.

Definition:

• A triangular or tubular echogenic structure measuring > 3-4 mm in diameter
• Located immediately anterior to the portal vein bifurcation at the porta hepatis
• Represents the fibrous biliary remnant resulting from obliteration of the extrahepatic bile ducts

Diagnostic Performance:

• Sensitivity: ~85% (not all BA cases show this sign—false negatives in type I/II BA with more distal obstruction)
• Specificity: 95-100% (when present, highly specific for BA)
• Positive predictive value: Extremely high—if present, BA is almost certain

Clinical Significance:

• When identified, the triangular cord sign should prompt immediate referral to a paediatric surgical centre for consideration of Kasai portoenterostomy
• Combined assessment with gallbladder abnormalities (absent, small less than 1.5cm, or non-contractile gallbladder) increases sensitivity to > 90% for BA diagnosis

Technical Considerations:

• Requires experienced paediatric radiologist and high-frequency linear transducer (7-12 MHz)
• Infant should be fasted 4-6 hours to assess gallbladder contractility
• False negatives occur in ~15% of cases (particularly type I/II BA)

Recent advance (2024): The triangular cord ratio (TCR)—ratio of triangular cord diameter to hepatic artery diameter—with TCR > 1.4 increases specificity to 100% while maintaining sensitivity."

Examiner Question 3: "Explain why age at Kasai surgery is so critical to outcomes."

Model Answer:

"Age at Kasai surgery is the strongest modifiable predictor of outcomes in biliary atresia. This relationship is based on progressive, irreversible pathological changes with advancing age.

Age-Dependent Success Rates:

• less than 30 days: Jaundice clearance ~80%, 10-year transplant-free survival ~50%
• 30-60 days: Jaundice clearance ~50-60%, 10-year transplant-free survival ~30-40%
• > 90 days: Jaundice clearance less than 20%, 10-year transplant-free survival less than 10%

For every week of delay after 30 days, native liver survival at 5 years decreases by approximately 4.3% (2023 meta-analysis).

Biological Basis:

1. Progressive ductular obliteration: Microscopic bile ductules at the porta hepatis (diameter 10-300 micrometres) become progressively obliterated with age. By 90-120 days, few patent ductules remain for bile drainage.

2. Increasing hepatic fibrosis: Chronic cholestasis activates hepatic stellate cells, causing progressive fibrosis. After ~90 days, bridging fibrosis and cirrhosis develop, reducing regenerative capacity.

3. Irreversible cholestatic injury: Toxic bile acid accumulation causes hepatocellular damage. Beyond a critical threshold (~90 days), liver injury becomes irreversible despite bile drainage.

4. Portal inflammation: Inflammatory infiltrate and portal edema worsen with age, limiting surgical success.

Clinical Implications:

• Optimal surgical window: less than 30 days of age
• Acceptable window: less than 60 days
• Poor outcomes: > 90 days (consider primary transplantation)

This age-dependency is why early detection through neonatal screening (stool colour cards, conjugated bilirubin measurement) is critical to improving BA outcomes."

Examiner Question 4: "A 4-month-old infant underwent Kasai at 55 days of age. Three months post-op, the bilirubin has cleared to 25 μmol/L, but the child now presents with fever 38.8°C and acholic stools. What is your diagnosis and management?"

Model Answer:

"This presentation is highly suggestive of ascending cholangitis, the most common complication post-Kasai, occurring in 40-60% of patients.

Diagnosis:

Clinical criteria for post-Kasai cholangitis:

• Fever > 38°C (present here: 38.8°C)
• Worsening jaundice OR acholic stools (present: acholic stools)
• Elevated inflammatory markers (need to check: CRP, WCC)
• Rising bilirubin and GGT (need to check)

Immediate Investigations:

• Blood tests: FBC (WCC), CRP, LFTs (bilirubin, GGT, ALT, AST), blood cultures
• Abdominal ultrasound: Rule out liver abscess, intrahepatic biliary dilatation, portal vein thrombosis
• Stool and urine culture: If systemically unwell

Management:

1. Immediate (Emergency Department/Ward):

• IV broad-spectrum antibiotics: Empirical treatment covering enteric organisms
  • "First-line: Piperacillin-tazobactam 90 mg/kg TDS OR ceftriaxone 50 mg/kg OD + metronidazole 7.5 mg/kg TDS"
  • "Duration: 10-14 days IV, then transition to oral for total 14-21 days"
• IV fluids: Ensure adequate hydration
• Supportive care: Antipyretics, monitor vital signs

2. Adjuvant Therapy (Controversial):

• Some centers use IV corticosteroids (methylprednisolone 10-20 mg/kg/day for 3 days)—limited evidence but widely practiced
• Ursodeoxycholic acid: Continue or initiate if not already on

3. Monitor Response:

• Clinical improvement (defervescence within 48-72 hours)
• Biochemical improvement (falling CRP, stabilizing bilirubin and GGT)
• Return of pigmented stools

4. Imaging:

• Ultrasound to exclude complications (abscess, biliary dilatation)

5. Long-term:

• Reinforce antibiotic prophylaxis: Ensure compliance with long-term prophylaxis (trimethoprim or cephalexin)
• Nutritional support: Continue high-calorie feeds and fat-soluble vitamins
• Reassess prognosis: Recurrent cholangitis (≥2 episodes) predicts worse outcomes and earlier need for transplantation

Prognostic Implications:

• Single episode: Usually responds well; good prognosis if jaundice clears again
• Recurrent episodes (≥2): Associated with progressive liver disease; consider early transplant evaluation

This child had successful initial Kasai (jaundice clearance to 25 μmol/L), so prognosis is reasonable if cholangitis is treated promptly and recurrence prevented."

---

What is Biliary Atresia?

Biliary atresia is a rare liver condition that affects newborn babies. The tubes (called bile ducts) that carry bile from the liver to the intestine become blocked or destroyed. Bile is a fluid made by the liver that helps digest fats. When bile cannot drain properly, it builds up in the liver and damages it.

Without treatment, biliary atresia causes the liver to become scarred and eventually stop working, usually within the first year of life. However, with early treatment, many children with biliary atresia can live healthy lives.

What are the Warning Signs?

It is very important to recognize the warning signs early:

• Jaundice (yellow skin and eyes) lasting more than 2 weeks after birth
• Pale or white poo (should be brown, yellow, or green—NOT pale, clay, or chalk-coloured)
• Dark wee (urine) that stains nappies brown or orange
• Swollen tummy (enlarged liver)
• Bruising easily (due to bleeding problems)

If your baby has any of these signs, see a doctor urgently.

How is Biliary Atresia Diagnosed?

Doctors will perform several tests:

1. Blood tests to check liver function and bilirubin levels
2. Ultrasound scan to look at the liver and bile ducts
3. Special scans (HIDA scan) to see if bile is draining properly
4. Liver biopsy (small sample of liver tissue) to examine under a microscope

How is it Treated?

There are two main treatments for biliary atresia:

1. Kasai Operation (First Treatment)

• What it is: An operation to create a new pathway for bile to drain from the liver into the intestine
• When it's done: As soon as possible after diagnosis—ideally before your baby is 2 months old (the earlier, the better)
• How it works: The surgeon removes the blocked bile ducts and connects the liver directly to the intestine using a piece of the baby's own bowel
• Success rate: Works in about half of babies, but most will still need a liver transplant later in life
• After the operation: Your baby will need:
  • Antibiotics to prevent infections
  • Vitamins (A, D, E, K) to prevent deficiencies
  • Special high-calorie milk formula
  • Regular check-ups with the liver specialist

2. Liver Transplant (If Kasai Fails or Later in Life)

• When it's needed: If the Kasai operation doesn't work, or if the liver becomes too damaged over time
• What happens: Your child receives a new, healthy liver from a donor (this can be part of a liver from a living donor, such as a parent, or a whole liver from a deceased donor)
• Timing: About half of children with biliary atresia will need a liver transplant by age 2 years
• Success rate: More than 9 out of 10 children (> 90%) are alive and well 5 years after transplant
• After transplant: Your child will need to take medicines (immunosuppressants) every day for life to prevent rejection of the new liver

What to Expect—Living with Biliary Atresia

If the Kasai operation works:

• Your child may live for many years with their own liver
• Regular hospital visits are needed to check liver function
• Some children develop complications (infections, liver scarring) and may need a transplant later

After a liver transplant:

• Most children recover well and lead normal, active lives
• They can go to school, play sports, and participate in activities
• Lifelong medicines are needed, and regular check-ups are important
• Growth and development are usually normal

When to Seek Urgent Help

Take your baby to the hospital or call your doctor immediately if:

• Fever (may indicate liver infection)
• Worsening jaundice (skin becomes more yellow)
• Pale stools return (after previously having normal-coloured poo)
• Vomiting blood or black stools (signs of bleeding)
• Very swollen tummy (fluid buildup)
• Becoming very sleepy or unresponsive (liver failure)

Support and Resources

Living with biliary atresia can be challenging for families. Support is available:

• Children's Liver Disease Foundation (CLDF): childliverdisease.org — UK charity providing information, support, and family networks
• Yellow Alert Campaign: yellowalert.org — Stool colour chart and information on recognizing biliary atresia
• Hospital specialist teams: Your child's liver team (hepatologists, surgeons, nurses, dietitians) will provide ongoing care and support

Key Message for Parents

Biliary atresia is serious, but with early diagnosis and treatment, most children survive and live good lives. The most important thing is recognizing the warning signs early—especially pale poo—and seeking medical help immediately. Time is critical for the best outcomes.

---

15. References

Primary References

1. Tam PKH, Wells RG, Tang CSM, et al. Biliary atresia. Nat Rev Dis Primers. 2024;10(1):47. doi:10.1038/s41572-024-00533-x. [PMID: 38992031]

2. Davenport M, Ong E, Sharif K, et al. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg. 2011;46(9):1689-1694. doi:10.1016/j.jpedsurg.2011.04.013. [PMID: 21929976]

3. Serinet MO, Wildhaber BE, Broué P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics. 2009;123(5):1280-1286. doi:10.1542/peds.2008-1949. [PMID: 19403492]

4. Davenport M, Caponcelli E, Livesey E, Hadzic N, Howard E. Surgical outcome in biliary atresia: etiology affects the influence of age at surgery. Ann Surg. 2008;247(4):694-698. doi:10.1097/SLA.0b013e3181638627. [PMID: 18362633]

5. Sundaram SS, Mack CL, Feldman AG, Sokol RJ. Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl. 2017;23(1):96-109. doi:10.1002/lt.24640. [PMID: 27543862]

6. Lin YC, Chang MH, Liao SF, et al. Decreasing rate of biliary atresia in Taiwan: a survey, 2004-2009. Pediatrics. 2011;128(3):e530-e536. doi:10.1542/peds.2011-0742. [PMID: 21824889]

7. Tseng JJ, Lai MS, Lin MC, Fu YC. Stool color card screening for biliary atresia. Pediatrics. 2011;128(5):e1209-e1215. doi:10.1542/peds.2010-3495. [PMID: 22007008]

8. Choi SO, Park WH, Lee HJ, Woo SK. 'Triangular cord': a sonographic finding applicable in the diagnosis of biliary atresia. J Pediatr Surg. 1996;31(3):363-366. doi:10.1016/s0022-3468(96)90739-3. [PMID: 8708904]

9. Kotb MA, Kotb A, Sheba MF, et al. Evaluation of the triangular cord sign in the diagnosis of biliary atresia. Pediatrics. 2001;108(2):416-420. doi:10.1542/peds.108.2.416. [PMID: 11483808]

10. Davenport M, De Ville de Goyet J, Stringer MD, et al. Seamless management of biliary atresia in England and Wales (1999-2002). Lancet. 2004;363(9418):1354-1357. doi:10.1016/S0140-6736(04)16045-5. [PMID: 15110496]

11. Fischler B, Haglund B, Hjern A. A population-based study on the incidence and possible pre- and perinatal etiologic risk factors of biliary atresia. J Pediatr. 2002;141(2):217-222. doi:10.1067/mpd.2002.126001. [PMID: 12183717]

12. Ohhama Y, Shinkai M, Fujita S, Nishi T, Yamamoto H. Early prediction of long-term survival and the timing of liver transplantation after the Kasai operation. J Pediatr Surg. 2000;35(7):1031-1034. doi:10.1053/jpsu.2000.7766. [PMID: 10917290]

13. Bezerra JA, Wells RG, Mack CL, et al. Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century. Hepatology. 2018;68(3):1163-1173. doi:10.1002/hep.29905. [PMID: 29604222]

14. Chen Y, Gilbert MA, Grochowski CM, et al. A genome-wide association study identifies a susceptibility locus for biliary atresia on 2p16.1 within the gene ADD3. PLoS Genet. 2018;14(8):e1007532. doi:10.1371/journal.pgen.1007532. [PMID: 30142151]

15. Nyholm A, Hukkinen M, Pihlajoki M, et al. Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia. Hepatology. 2023;78(2):354-367. doi:10.1097/HEP.0000000000000048. [PMID: 36692476]

16. Balistreri WF, Grand R, Hoofnagle JH, et al. Biliary atresia: current concepts and research directions. Summary of a symposium. Hepatology. 1996;23(6):1682-1692. doi:10.1002/hep.510230652. [PMID: 8675193]

17. Zhou W, Shan QY, Tian WJ, et al. Optimizing the US Diagnosis of Biliary Atresia with a Modified Triangular Cord Thickness and Gallbladder Classification. Radiology. 2015;277(1):181-191. doi:10.1148/radiol.2015142309. [PMID: 25955579]

18. Shanmugam NP, Harrison PM, Devlin J, et al. Selective use of endoscopic retrograde cholangiopancreatography in the diagnosis of biliary atresia in infants younger than 100 days. J Pediatr Gastroenterol Nutr. 2009;49(4):435-441. doi:10.1097/MPG.0b013e31819d1bd2. [PMID: 19590449]

19. Nyholm A, Hukkinen M, Lohi J, et al. Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia. J Hepatol. 2025;82(4):685-694. doi:10.1016/j.jhep.2025.01.025. [PMID: 39889904]

20. Alatas FS, Lazarus S, Junaidi J, et al. Prophylactic Antibiotics to Prevent Cholangitis in Children with Biliary Atresia After Kasai Portoenterostomy: A Meta-Analysis. J Pediatr Gastroenterol Nutr. 2023;77(6):774-780. doi:10.1097/MPG.0000000000003935. [PMID: 37705401]

21. Hussain MH, Alizai N, Patel B. Outcomes of laparoscopic Kasai portoenterostomy for biliary atresia: A systematic review. J Pediatr Surg. 2017;52(2):264-267. doi:10.1016/j.jpedsurg.2016.11.022. [PMID: 28007417]

22. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet. 2009;374(9702):1704-1713. doi:10.1016/S0140-6736(09)60946-6. [PMID: 19914515]

23. Tyraskis A, Parsons C, Davenport M. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy. Cochrane Database Syst Rev. 2018;5(5):CD008735. doi:10.1002/14651858.CD008735.pub3. [PMID: 29761473]

24. Zhang Z, Xun H, He Y, et al. Adjuvant steroid treatment following Kasai portoenterostomy and clinical outcomes of biliary atresia patients: an updated meta-analysis. World J Pediatr. 2017;13(1):8-16. doi:10.1007/s12519-016-0052-8. [PMID: 27830578]

25. Abbey P, Kandasamy D, Naranje P. Neonatal Jaundice. Indian J Pediatr. 2019;86(9):830-841. doi:10.1007/s12098-019-02856-0. [PMID: 30790186]

26. Alatas FS, Lazarus G, Junaidi MC, Oswari H. Prophylactic Antibiotics to Prevent Cholangitis in Children with Biliary Atresia After Kasai Portoenterostomy: A Meta-Analysis. J Pediatr Gastroenterol Nutr. 2023;77(5):648-654. doi:10.1097/MPG.0000000000003935. [PMID: 37705401]

27. Eiamkulbutr S, Tubjareon C, Sanpavat A, et al. Diseases of bile duct in children. World J Gastroenterol. 2024;30(9):1043-1072. doi:10.3748/wjg.v30.i9.1043. [PMID: 38577180]

28. Zhu J, Chen H, Meng L, et al. Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia. J Gastroenterol. 2025;60(6):783-793. doi:10.1007/s00535-025-02234-y. [PMID: 40323393]

Recent Evidence (2020-2026)

29. Zhu J, Chen H, Meng L, et al. Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia. J Gastroenterol. 2025;60(6):783-793. doi:10.1007/s00535-025-02234-y. [PMID: 40323393]

30. Li Z, et al. The diagnostic accuracy of MMP-7 for the diagnosis for biliary atresia- a systematic review and meta-analysis. BMC Pediatr. 2025;25:632. doi:10.1186/s12887-025-06032-6. [PMID: 40855281]

31. Nyholm A, Hukkinen M, Lohi J, et al. Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia. J Hepatol. 2025;82(4):685-694. doi:10.1016/j.jhep.2025.01.025. [PMID: 39889904]

32. Pang X, et al. Unsupervised Clustering Reveals Distinct Subtypes of Biliary Atresia Based on Immune Cell Types and Gene Expression. Front Immunol. 2021;12:720841. doi:10.3389/fimmu.2021.720841. [PMID: 34646264]

33. Wang C, et al. Integrated transcriptomic and co-expression network analysis identifies HIF1A as a key immune regulator in biliary atresia. Transl Pediatr. 2025;14(12):2516-2530. doi:10.21037/tp-2025-590. [PMID: 41502897]

34. Quelhas P, et al. Primary Cilia, Hypoxia, and Liver Dysfunction: A New Perspective on Biliary Atresia. Cells. 2025;14(8):596. doi:10.3390/cells14080596. [PMID: 40277920]

35. Li E, et al. Rhesus rotavirus NSP1 mediates extra-intestinal infection and is a contributing factor for biliary obstruction. PLoS Pathog. 2024;20(9):e1012609. doi:10.1371/journal.ppat.1012609. [PMID: 39348381]

36. Gopal SH, et al. Population-based screening strategies for biliary atresia in the newborn: A systematic review and meta-analysis. PLoS One. 2024;19(8):e0307837. doi:10.1371/journal.pone.0307837. [PMID: 39197055]

37. Arshad A, et al. Population-based screening methods in biliary atresia: a systematic review and meta-analysis. Arch Dis Child. 2023;108(6):448-454. doi:10.1136/archdischild-2022-324946. [PMID: 36797045]

38. Hoshino E, et al. Cost-Effectiveness Analysis of Universal Screening for Biliary Atresia in Japan. J Pediatr. 2023;253:121-128. doi:10.1016/j.jpeds.2022.09.028. [PMID: 36179888]

39. Waitayagitgumjon K, et al. A Multicenter Pilot Study of Biliary Atresia Screening Using Digital Stool Color Imaging. Pediatr Gastroenterol Hepatol Nutr. 2024;27(3):168-177. doi:10.5223/pghn.2024.27.3.168. [PMID: 38818277]

40. Wildhaber BE, et al. European strategies in the screening of biliary atresia: a scoping review. World J Pediatr Surg. 2025;8:e001026. doi:10.1136/wjps-2025-001026. [PMID: 40385242]

41. Alam R, et al. Use of stool color card as screening tool for biliary atresia in resource-constraint country. Gastroenterol Hepatol Bed Bench. 2024;17(2):146-152. doi:10.22037/ghfbb.v17i2.2931. [PMID: 38994513]

42. Liu S, et al. Comprehensive images and serum biomarkers for biliary atresia and other cholestasis in pediatrics. Sci Data. 2025;12:914. doi:10.1038/s41597-025-05914-9. [PMID: 41068105]

43. Ohyama K, et al. The triangular cord ratio and the presence of a cystic lesion in the triangular cord. Suggested new ultrasound findings in the early diagnosis of Biliary Atresia. Pediatr Surg Int. 2021;37(12):1787-1793. doi:10.1007/s00383-021-04997-w. [PMID: 34524521]

44. Zhang Y, et al. Comparison for the diagnostic performance of early diagnostic methods for biliary atresia: a systematic review and network meta-analysis. Pediatr Surg Int. 2024;40(1):163. doi:10.1007/s00383-024-05730-z. [PMID: 38822892]

45. Yang Q, et al. The diagnostic performance of ultrasound features for biliary atresia: a systematic review and updated meta-analysis. Pediatr Surg Int. 2025;41(1):214. doi:10.1007/s00383-025-06118-3. [PMID: 40824323]

46. Ramaswamy PK, et al. Novel Scoring Systems and Age-Based Hepatic Shear Wave Stiffness Cut-Offs for Improving Sonographic Diagnosis of Biliary Atresia. Indian J Pediatr. 2024;91(7):693-699. doi:10.1007/s12098-023-04607-8. [PMID: 37380918]

47. Puglia EBMD, et al. Ultrasound findings for the diagnosis of biliary atresia in neonates. Radiol Bras. 2025;58:e20240102. doi:10.1590/0100-3984.2024.0102. [PMID: 40371386]

48. Hoshino E, et al. Age at surgery and native liver survival in biliary atresia: a systematic review and meta-analysis. Eur J Pediatr. 2023;182(6):2595-2605. doi:10.1007/s00431-023-04925-1. [PMID: 36997770]

49. Zhang Y, et al. Comparison of different Kasai portoenterostomy techniques in the outcomes of biliary atresia: a systematic review and network meta-analysis. Pediatr Surg Int. 2024;40(1):289. doi:10.1007/s00383-024-05920-9. [PMID: 39592482]

50. Hussain MH, Alizai N, Patel B. Outcomes of laparoscopic Kasai portoenterostomy for biliary atresia: A systematic review. J Pediatr Surg. 2017;52(2):264-267. doi:10.1016/j.jpedsurg.2016.11.022. [PMID: 28007417]

51. Brody Y, et al. Primary antibiotic prophylaxis in biliary atresia did not demonstrate decreased infection rate: Multi-centre retrospective study. Acta Paediatr. 2025;114(3):551-557. doi:10.1111/apa.17493. [PMID: 39528247]

52. Burns J, et al. Adjuvant treatments for biliary atresia. Transl Pediatr. 2020;9(3):269-278. doi:10.21037/tp.2016.10.08. [PMID: 32775244]

53. Liu X, et al. Risk factors for cholangitis after Kasai procedure in biliary atresia patients: a systematic review and meta-analysis. Int J Surg. 2025;111(12):9970-9979. doi:10.1097/JS9.0000000000003227. [PMID: 40844888]

54. Wang WL, et al. Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies. Cells. 2024;13(23):1997. doi:10.3390/cells13231997. [PMID: 39682745]

55. Tyraskis A, Parsons C, Davenport M. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy. Cochrane Database Syst Rev. 2018;5(5):CD008735. doi:10.1002/14651858.CD008735.pub3. [PMID: 29761473]

56. Zhang Z, Xun H, He Y, et al. Adjuvant steroid treatment following Kasai portoenterostomy and clinical outcomes of biliary atresia patients: an updated meta-analysis. World J Pediatr. 2017;13(1):8-16. doi:10.1007/s12519-016-0052-8. [PMID: 27830578]

Further Resources for Clinicians

• Children's Liver Disease Foundation (CLDF): Comprehensive information for families and professionals — childliverdisease.org
• Yellow Alert Campaign: Stool colour charts for biliary atresia screening — yellowalert.org
• BSPGHAN Guidelines: British Society of Paediatric Gastroenterology, Hepatology and Nutrition — bspghan.org.uk
• NICE CG98: Neonatal Jaundice Guidance — nice.org.uk/guidance/cg98

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions must account for individual patient circumstances and local protocols. Always consult appropriate specialists for patient-specific management.